title: Fractionated intravenous administration of 90Y-labeled B72.3 GYK-DTPA immunoconjugate in beagle dogs.
abstract: B72.3, a monoclonal antibody with reactivity against human adenocarcinomas, was coupled with linker-chelator GYK-DTPA using carbohydrate mediated conjugation chemistry and radiolabeled with yttrium-90. Single and double intravenous injections of radioimmunoconjugate were compared for acute and late normal tissue toxicity in 15 beagle dogs. The second injection was given 4 or 8 days after the first. Pharmacokinetics of the radioimmunoconjugate in blood, bone marrow and urine were similar for first and second injections. Only bone marrow (acute) and liver (late) toxicity were observed. Both liver and bone marrow toxicity were decreased by fractionation of the injections. After double injections, the total equitoxic dose was 15 and 60% higher for bone marrow and liver toxicity, respectively. The mechanisms of normal tissue protection offered by fractionated radioimmunoglobulin therapy (RIT) remain to be defined. Fractionated RIT will have a better therapeutic ratio than single injection RIT, if antitumor effects appear to be less susceptible to fractionation than normal tissues.
authors.affiliation: Johns Hopkins Oncology Center, Section of Radiobiology, Baltimore, MD 21205.
authors.forename: H M
authors.initials: HM
authors.lastname: Vriesendorp
authors.forename: Y
authors.initials: Y
authors.lastname: Shao
authors.forename: J E
authors.initials: JE
authors.lastname: Blum
authors.forename: S M
authors.initials: SM
authors.lastname: Quadri
authors.forename: J R
authors.initials: JR
authors.lastname: Williams
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D000912:Antibodies, Neoplasm / Q000008:administration & dosage; D004285:Dogs; D005260:Female; D006207:Half-Life; D007262:Infusions, Intravenous; D008297:Male; D009842:Oligopeptides / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000633:toxicity; D004369:Pentetic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000633:toxicity; D015021:Yttrium Radioisotopes / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000633:toxicity
chemical_list: D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D009842:Oligopeptides; D015021:Yttrium Radioisotopes; C062250:glycyl-tyrosyl-lysine-DTPA; D004369:Pentetic Acid